Secure your spot at Vitalist Bay

Erick Brimen is an entrepreneur and investor with extensive experience in finance and socioeconomic development. He is the founder and CEO of Próspera, a special economic zone in Honduras designed to foster economic growth and innovation. He served as CFO for Latin America at the Borealis Group, where he led the creation of multiple business units. As an entrepreneur, Erick founded ComparaMejor.com, a leading online insurance brokerage in Colombia, and NeWay Capital, focusing on alternative real estate strategies that drive socioeconomic development.

James Arrowood is an entrepreneur, legal expert, and executive with extensive experience in the life extension and biotechnology sectors. He is the CEO of the Alcor Life Extension Foundation, where he has been instrumental in guiding the organization since 2015. James initially joined Alcor as outside General Counsel, helping navigate complex legal and business challenges. He has also served on the board of directors for a major local non-profit and as its public relations chair, contributing to his long-standing expertise in media and public relations. His work focuses on advancing Alcor’s mission and engaging with the wider conversation on cutting-edge technologies aimed at extending human lifespan.

Ralf Spindler is a leading scientist and innovator with extensive expertise in neural systems cryopreservation. As the Head of Neural Systems Cryopreservation at 21st Century Medicine, he plays a pivotal role in advancing preservation techniques critical to the field of cryobiology. With a background in electrical and biomedical engineering, Ralf's research focuses on improving methods to preserve the human brain and other neural structures at ultra-low temperatures, with the goal of ensuring their integrity for future revival. His work is at the forefront of bridging the gap between cutting-edge science and long-term human preservation.

Ralph C. Merkle is a computer scientist and cryptographer with over 40 years of experience in academic research and technological innovation. He is a board member at the Alcor Life Extension Foundation, an organization focused on cryonics and life extension. Ralph's scientific background encompasses public key cryptography, cryptographic hashing, and nanotechnology. His work aims to advance secure communication systems and explore technologies to extend human life.

Alexandru Băcița is a scientist and entrepreneur with extensive experience in drug discovery and development. He is the co-founder and Chief Operating Officer of The Cat Health Company (TCHC), a biotech startup dedicated to extending feline longevity through innovative therapies. Before co-founding TCHC, Alexandru served as a Senior Scientist at Charles River Laboratories, a leading provider of services for drug discovery and clinical trials. At TCHC, Alexandru focuses on developing computational pipelines to predict new therapies for rare diseases and age-related conditions in cats. His work aims to enhance feline health and longevity, providing pets with longer, healthier lives

Alan Tomusiak is a researcher specializing in the biology of aging, with a focus on epigenetics and immunology. For his PhD, he studied in the Verdin Lab at the Buck Institute for Research on Aging. His research focuses on developing novel epigenetic clocks that are resistant to changes in immune cell composition, aiming to improve the accuracy of biological age predictions. Alan has also explored the effects of senolytic compounds on DNA methylation clocks, contributing to the understanding of how these interventions may influence biological aging. Through his work, Alan aims to uncover the molecular mechanisms underlying aging and develop interventions to promote healthy longevity.

Aschwin de Wolf is a Dutch-born American cryobiologist and entrepreneur with extensive experience in cryonics research and writing. He is the co-founder and Chief Executive Officer of Advanced Neural Biosciences (ANB), a biomedical research company established in 2008. ANB focuses on developing low-temperature technologies to preserve central nervous tissue and whole brains, aiming to advance brain banking, pharmacological drug discovery, and the study of neurodegenerative diseases. He co-authored the first comprehensive human cryopreservation procedures manual and authored the first medical biostasis protocol. Aschwin's involvement in cryonics extends to founding the Depressed Metabolism blog in 2007, which later evolved into Biostasis.com. He also co-founded and served as president of the Institute for Evidence-Based Cryonics. Through his work, Aschwin aims to advance the science and application of cryopreservation techniques, contributing to the potential for future medical applications and the extension of human life.

Nish Bhat is an entrepreneur and investor with extensive experience in biotechnology and venture capital. He is the Founder and General Partner of Carbon Silicon Ventures, a firm dedicated to supporting startups that integrate engineering principles with biological sciences to drive innovation in healthcare. Before establishing Carbon Silicon Ventures, Mr. Bhat co-founded Color Health, Inc. in 2013, a company specializing in genetic testing services for various hereditary cancers. He also co-founded SciFounders, a venture capital firm launched in 2021, and serves on the board of Reference Medicine, a company focused on making specimens more affordable and accessible for oncology diagnostic developers. His journey reflects a commitment to advancing the intersection of biology and engineering, aiming to transform healthcare through innovative solutions.

‍

Dr. Morgan Levine is a prominent scientist specializing in the biology of aging, with extensive experience in academic research and computational biology. She currently serves as the Vice President of Computation at Altos Labs, a biotechnology company focused on restoring cell health and resilience through cell rejuvenation. Dr. Levine's scientific background encompasses bioinformatics, cellular biology, complex systems, and biostatistics. She is renowned for developing innovative methods to quantify the molecular and physiological changes that occur over an organism's lifetime, integrating interdisciplinary approaches to track the trajectories of aging cells and organisms. Her vision includes creating multi-scale computational models to elucidate how dynamic molecular states of cells lead to health and disease manifestations at various biological levels. Her work aims to uncover the principles of aging and develop interventions to promote healthy longevity.

Dr. Sam Rodriques is a physicist, bioengineer, and entrepreneur with extensive experience in academic research and biotechnology innovation. He is the founder and CEO of FutureHouse, a research lab in San Francisco dedicated to developing an AI Scientist to accelerate scientific discovery. Before establishing FutureHouse in 2023, Dr. Rodriques led the Applied Biotechnology Laboratory at the Francis Crick Institute, where he focused on integrating bioengineering and business to advance medical and biological research. His notable inventions include technologies for spatial and temporal transcriptomics, brain mapping, gene therapy, and nanofabrication. Throughout his career, Dr. Rodriques has been committed to accelerating scientific research through innovative technologies and interdisciplinary approaches. His work aims to revolutionize the pace of discovery and provide global access to cutting-edge scientific, medical, and engineering expertise.

Madam Mitochondria focuses on sharing research related to mitochondria, often highlighting the role of mitochondrial function in aging, diseases, and cellular health. She is known for her engaging and informative presence on social media, particularly on Twitter, where she shares insights and developments related to mitochondrial science. Her efforts contribute to a greater public understanding of the vital role mitochondria play in cellular energy production and overall well-being.

‍

Dr Jack Scannell is best known for his work to diagnose the causes of the progressive decline in R&D productivity in the drug and biotechnology industry. He coined the term “Eroom’s Law” (from computer science’s “Moore’s Law” spelled backwards) to describe the contrast between falling biopharma R&D output efficiency since 1950 in the face of spectacular gains in basic science and in the brute force efficiency of the scientific activities on which drug discovery is generally believed to depend. His work has considered the contributions of scientific, economic, regulatory, and organisational factors. Recently, he has focused on the predictive validity of screening and disease models in drug R&D, which constitute perhaps the major productivity bottleneck. Dr Scannell is currently the CEO of Etheros Pharmaceuticals Corp. Etheros is developing small molecule enzyme mimetics, based on fullerene chemistry, for age-related and neurodegenerative diseases. He is an Associate of the Department of Science, Technology, and Innovation Studies at Edinburgh University. He led Discovery Biology at e-Therapeutics PLC, an Oxford-based biotech firm. He has experience in drug and biotech investment at UBS and at Sanford Bernstein where he ran the European Healthcare teams. He has a Ph.D. in neuroscience from Oxford University and a degree in medical sciences from Cambridge University.

Dr. Dave Messina is an entrepreneur and scientist with over 25 years of experience in computational biology and human genetics. He serves as General Partner at Pioneer Fund and leads the Future of Health Fund. Prior to joining Pioneer Fund, Dr. Messina co-founded Cofactor Genomics, a company specializing in RNA and machine-learning-based diagnostics, where he led the development and clinical application of innovative diagnostic tools. Through his leadership at Pioneer Fund, he aims to advance the development of innovative health and biotechnology solutions, leveraging his extensive experience to support groundbreaking startups in the industry.

Chase Denecke is an entrepreneur and scientist with extensive experience in computational biology and biotechnology. He is the founder and Chief Executive Officer of Bootstrap Bio, a company specializing in advanced biotechnological research and development. Through his leadership at Bootstrap Bio, Mr. Denecke aims to advance the development of innovative biotechnological solutions, leveraging his expertise to address complex challenges in the field.

Dr. Tomer Landsberger is an entrepreneur and scientist with extensive experience in immunology and systems biology. He is the co-founder of Sciborg DAO, an organization dedicated to prolonging and enhancing human existence through the development of synthetic replacements, aiming to conquer death and enable long-term preservation of consciousness. Dr. Landsberger's scientific background includes significant contributions to the understanding of immune surveillance and senescence. Through his leadership at Sciborg DAO, Dr. Landsberger aims to integrate cutting-edge scientific research with collaborative, decentralized approaches to address the fundamental challenges of aging and mortality.

Dr. Molly Maloof is a physician, entrepreneur, and educator with over a decade of experience in health optimization and personalized medicine. She is the founder and CEO of Adamo Bioscience, a company pioneering the science of love and human connection to enhance health and longevity. Through her leadership at Adamo Bioscience, Dr. Maloof is developing biological, psychological, psychedelic, and technological solutions to foster love and connection, aiming to create a healthier, happier, and more resilient world.

Jasmine Smith is an entrepreneur and health information specialist with a diverse background in health data management and community engagement. She is the Chief Executive Officer of Rejuve.AI, a decentralized AI-driven longevity research network committed to making healthspan extension solutions accessible and affordable to all. Under her leadership, Rejuve.AI leverages artificial intelligence and blockchain to unite individuals, clinics, researchers, and health supply vendors, fostering collaborative efforts to discover and develop interventions that promote healthy longevity. Through her work at Rejuve.AI, Ms. Smith aims to democratize access to longevity solutions, ensuring that advancements in healthspan extension benefit people worldwide.

Borys Wróbel is a biologist and computer scientist with extensive experience in academic research and leadership. He serves as the Scientific Director of the European Institute for Brain Research (EIBR), where he is pioneering the development of a brain bank utilizing innovative methods to preserve neural tissue at the nanoscale level. Dr. Wróbel's interdisciplinary research spans brain banking, computational neuroscience, computational biology, and molecular biology. In his role at EIBR, Dr. Wróbel is dedicated to advancing the preservation of neural structures, aiming to enhance our understanding of the brain and its complexities.

Brian G. Wowk is a medical physicist and cryobiologist with over 20 years of experience in cryobiological research and technology development. He serves as the Chief Technology Officer at 21st Century Medicine, where he has been instrumental in advancing cryopreservation techniques. In his role at 21st Century Medicine, Dr. Wowk continues to lead efforts in developing advanced cryobiological technologies, aiming to improve the preservation and longevity of biological tissues and organs. Dr. Wowk's notable contributions include the discovery and development of synthetic molecules that mimic natural antifreeze proteins, commonly referred to as "ice blockers." These innovations have been pivotal in enabling the vitrification and successful transplantation of complex mammalian organs, such as kidneys. He is presently refining electromagnetic warming methods for vitrified whole organs.

Travis Timmerman is an associate professor and chair of the Department of Philosophy at Seton Hall University. Professor Timmerman's research interests encompass normative ethics, applied ethics, and the philosophy of death. He has contributed to discussions on topics such as the actualism/possibilism debate, axiological issues concerning the concept of "harm," animal welfare and global poverty. His recent works include "Probabilism" in the Journal of the American Philosophical Association (2024, co-authored with Yishai Cohen) and "The Negative Impact on Well-Being Account of Harm," forthcoming in the Oxford Handbook of Harm. Beyond his academic role, Professor Timmerman serves as a researcher for Rethink Priorities, focusing on the Moral Weight Project. He is currently authoring a book on the philosophy of death, under contract with Oxford University Press, aiming to deepen the understanding of mortality and its ethical implications.

Dr. Orion Taraban is a licensed psychologist with over a decade of experience in clinical practice. He is the creator and host of PsycHacks, a popular platform that offers brief, thought-provoking episodes several times a week on a variety of psychological topics inspired by his clinical work. PsycHacks has garnered significant attention, with over one hundred million views on YouTube, establishing Dr. Taraban as a thought leader in popular psychology. Dr. Taraban's professional focus centers on relationships and personal development. Through his work, he has assisted thousands of individuals in achieving their personal growth and relationship goals. His mission is to reduce unnecessary suffering by inspiring listeners and viewers to see themselves and their world in a new light.

Andrés Gómez Emilsson is a consciousness researcher and transdisciplinary scientist exploring the nature of subjective experience. He is the Director of Research at the Qualia Research Institute, an organization dedicated to developing a precise scientific understanding of qualia and its implications for well-being. His work integrates insights from neuroscience, computational modeling, and philosophy to advance the study of consciousness. Andrés is particularly interested in the structure of phenomenology, the neurotechnology of altered states, and the ethical implications of enhancing subjective experience. Through his research, he aims to uncover fundamental principles of consciousness and develop frameworks for its rigorous quantification and optimization.

Nathan Price is a scientist and entrepreneur with extensive experience in systems biology and biomedical research. He is the Chief Scientific Officer at Thorne and the Co-Director of the Center for Human Healthspan and Professor at the Buck Institute for Research on Aging. Nathan’s work focuses on leveraging multi-omics data, AI, and personalized health strategies to optimize human longevity and disease prevention. His research spans computational biology, precision medicine, and the development of interventions to promote healthy aging. Through his leadership in both academia and industry, he aims to transform healthcare by advancing science-driven approaches to longevity and well-being.

Erik Van Winkle is an entrepreneur and operations strategist with extensive experience in decentralized science and blockchain technology. He is the Head of Operations at DeSci Labs, an organization focused on leveraging decentralized technologies to advance scientific research and innovation. Erik’s work centers on building infrastructure for open collaboration, improving research accessibility, and integrating Web3 principles into the scientific ecosystem. Through his leadership, he aims to drive the transformation of scientific funding, publishing, and data-sharing to accelerate breakthroughs in biotechnology and beyond.

Kris Borer is an entrepreneur, technologist, and angel investor with a diverse background in technology leadership and philosophical authorship. He has served as Chief Technology Officer at multiple organizations, including MetLife Legal Plans, Willing, Inc., and KeyMe, where he led technological innovations and infrastructure development. Beyond his technological endeavors, Kris is the author of "The Ethics of Anarcho-Capitalism," a work that explores the philosophical foundations of a stateless, free-market society. Through his investments and thought leadership, Kris aims to foster innovation and ethical considerations in technology and societal structures.

Rebecca Ziegler is a cryonics specialist with a focus on advancing human cryopreservation technologies. She helped organize the 2024 Global Cryonics Summit, which brought together cryonics experts to develop a cohesive cryonics community and spark new ideas. She served as a Product Manager at Tomorrow Bio, a company dedicated to making cryonics more accessible and reliable through state-of-the-art preservation techniques and emergency standby services. Now she serves as a Director at the Cryosphere Foundation, with the goal to bring together experts and foster a cohesive cryonics community. Her work aims to refine cryonics processes and make human cryopreservation more accessible and effective.

‍

Eric Magro is an entrepreneur and advocate for life extension, dedicated to advancing the fields of cryonics and longevity policy. He is the Co-Founder of Cryosphere, a platform focused on fostering community and innovation in cryonics. As Director of Operations at LongeviPAC, Eric works to shape policies that support life extension technologies and research. He helped organize the 2024 Global Cryonics Summit, which brought together experts to provide the space and resources to push projects forward. His efforts bring together scientific progress and public policy, ensuring that advancements in longevity science receive the attention and support they deserve. Through his work, Eric aims to accelerate the development of life-preserving technologies and expand access to cutting-edge longevity solutions.

‍

Max Marty is a serial entrepreneur and active member of the cryonics community. In 2011, Max co-founded Blueseed, a project aimed at creating a floating startup incubator off the coast of California. The initiative sought to provide a visa-free environment for international entrepreneurs to collaborate and innovate near Silicon Valley. He is the creator of The Cryosphere, an online cryonics-focused community, fostering discussions among enthusiasts and professionals. He helped organize the 2024 Global Cryonics Summit, which connected experts from the industry and community. Max also co-hosts The Cryosphere Podcast, where he engages with key figures in the field to explore the scientific, social, and philosophical aspects of cryonics. Through his initiatives, Max aims to advance public understanding and acceptance of cryonics as a viable option for life extension. Max's diverse entrepreneurial ventures reflect his commitment to pioneering unconventional solutions and fostering global collaboration in technology and life extension.

‍

Daniel Walters is a prominent advocate for cryonics and life extension, with extensive experience in community engagement and digital outreach. He is the co-host of the Cryosphere Podcast, where he explores the latest advancements, challenges, and philosophies surrounding cryopreservation. He helped organize the 2024 Global Cryonics Summit, which brought together experts to foster a cohesive cryonics community. With deep roots in the cryonics community, Daniel has played a key role in fostering discussion and awareness. As Community Outreach Coordinator at Alcor Life Extension Foundation, Daniel is focused on transforming Alcor’s digital presence by enhancing member communications, expanding social media engagement, and modernizing its online platforms. His work bridges the gap between scientific progress and public awareness, ensuring that cryonics continues to gain traction as a viable approach to life extension.

Goktug Yilmaz is an entrepreneur and software developer passionate about creating engaging digital experiences. He is the founder of Colonist.io, a popular online board game platform that brings strategy enthusiasts together from around the world. With a background in computer science and a deep interest in game design, Goktug has dedicated his career to building intuitive and scalable software. Drawing on his experience in designing user-centered applications, he is interested in how digital tools can enhance health tracking, improve stress management, and optimize performance. His work focuses on enhancing user experience and fostering online communities through innovative and accessible gameplay.

Xiaoxi Wei is an entrepreneur, scientist, and inventor specializing in biomimetic nanoscience and biopreservation for regenerative medicine. She is the founder and CEO of X-Therma, a pioneering company developing breakthrough ice prevention technologies to enable organ preservation and transplantation. With a vision to make "on-demand organs" a reality, Xiaoxi has dedicated her career to advancing cryopreservation and regenerative medicine. Her scientific expertise lies in supramolecular assembly and biomimetic chemistry. A recognized leader in her field, Xiaoxi has served as a healthcare advisor for the UC Regents Working Group on Innovation Transfer and Entrepreneurship, a scientific advisor to the Life Extension Foundation, and Vice Chair of the Younger Chemists Committee of the American Chemical Society. As a distinguished member of the RULEBREAKER Society in Germany, she continues to push the boundaries of science and innovation to revolutionize organ transplantation and regenerative medicine.

​Kian Sadeghi is an entrepreneur with a background in computational biology. He is the founder and CEO of Nucleus, a consumer health platform leveraging whole-genome sequencing to provide comprehensive genetic health insights. Kian's vision is to empower individuals with personalized health information to mitigate disease risks and promote well-being. Under his leadership, Nucleus has secured significant funding from prominent investors, including Alexis Ohanian's Seven Seven Six and Peter Thiel's Founders Fund. The platform integrates genetic data with lifestyle factors to deliver actionable health insights, aiming to revolutionize preventive healthcare.

​Nico Arcino is a seasoned technology leader with extensive experience in both dynamic startups and large foundational institutions. He currently serves as the Chief Technology Officer at Primasun, a company dedicated to advancing sleep health through innovative technological solutions. Prior to joining Primasun, Nico held the position of Senior Director of Strategic Partnerships at Kaiser Permanente, where he played a pivotal role in forging collaborations that enhanced healthcare delivery and technological integration. Throughout his career, Nico has been recognized as a health and tech innovator, consistently contributing to advancements at the intersection of healthcare and technology. His diverse background and strategic insights continue to drive Primasun's mission to revolutionize sleep health.

​Dr. Sajad Zalzala is a physician and entrepreneur with over 15 years of experience in family medicine and a strong focus on preventive health and longevity. He co-founded AgelessRx in 2019, serving as Chief Medical Officer, where he leverages his expertise to offer treatments aimed at slowing down the aging process and enhancing overall health. His dedication to addressing the root causes of symptoms and illness led him to specialize in functional medicine, ultimately guiding his transition into the field of longevity. Through AgelessRx, Dr. Zalzala aims to make longevity treatments accessible, empowering individuals to take proactive steps toward healthier, longer lives.

​Dr. Anna Vakhrusheva is a bioengineer and entrepreneur specializing in anti-aging therapies, immunology, and drug development. She currently serves as the Chief Technology Officer (CTO) at Unlimited Bio, where she leads the development of gene therapies aimed at promoting healthy longevity. Her career includes significant roles such as CEO of Betuvax, a company focused on vaccine development from research and development to clinical trials, and lead bioengineer at Longaevus Technologies, where she explored her interests in anti-aging therapies and drug development. Through her leadership at Unlimited Bio, Dr. Vakhrusheva continues to contribute to advancements in biotechnology, focusing on interventions that promote healthy longevity and improve quality of life.

​Ivan Morgunov is an entrepreneur and advocate for longevity science, with a focus on developing genetic therapies aimed at combating aging. He is the CEO and co-founder of Unlimited Bio, a company dedicated to creating rejuvenation treatments through advanced gene therapy techniques. Ivan's journey into the longevity field began over seven years ago, driven by a personal commitment to exploring diverse pathways to healthy aging and extending human lifespan. Prior to founding Unlimited Bio, he established Longaevus Technologies, a venture studio focused on longevity research, where he led efforts to discover innovative approaches to reducing chronic diseases associated with aging. With over five years of experience in leading successful projects and startups, Ivan has demonstrated a strong ability to drive scientific initiatives from concept to implementation. His leadership at Unlimited Bio reflects his dedication to translating cutting-edge scientific research into practical solutions for aging, aiming to make significant strides in the field of life extension. Through his work, Ivan Morgunov continues to contribute to the advancement of biotechnology, focusing on interventions that promote healthy longevity and improve quality of life.

Boyang Wang is an entrepreneur and investor with a strong background in computer science and a passion for the gaming and longevity industries. He is the founder of Immortal Dragons, a purpose-driven longevity fund dedicated to advancing research and innovation in life extension technologies. In addition to his entrepreneurial ventures, Boyang actively contributes to the longevity community. He serves as a senior venture fellow at Healthspan Capital, one of the most active longevity-focused venture capital funds. His engagement extends to speaking at conferences and participating in podcasts, where he shares insights on the convergence of technology, gaming, and life extension. Through his diverse endeavors, Boyang Wang continues to influence both the gaming industry and the field of longevity, driving forward initiatives that blend technological advancement with human health and well-being.

​Sonia Arrison is a best-selling author, analyst, entrepreneur, and investor with over two decades of experience studying the impact of new technologies on society. She is the founder of 100 Plus Capital, Lead Venture Partner at Portfolia, and serves as an advisor to Felicis Ventures, organizations that invest at the convergence of biology and technology. Sonia focuses her efforts on exponentially growing technologies and their societal implications. Her most recent book, 100 Plus: How the Coming Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith, addresses the social, economic, and cultural impacts of radical human longevity. Through her diverse endeavors, Sonia Arrison continues to influence the discourse on technology's role in shaping the future, particularly in the realms of human longevity and societal transformation.

Dr. Koji Tanabe is a pioneering expert in induced pluripotent stem cells (iPSCs) with a strong track record in both research and business. He was a key contributor and co-author of the groundbreaking study that led to the world’s first successful establishment of human iPSCs, a discovery that earned the Nobel Prize. Under his leadership, I Peace has pioneered scalable, high-quality iPSC manufacturing and is at the forefront of developing iPSC-based applications for rejuvenation. His contributions to the industry earned him recognition as one of World Biz Magazine’s “Top 100 Innovation CEOs” in 2021.

Jonathan Anomaly works with a company that offers embryo selection for polygenic traits. Before this, he was a professor who taught classes at Duke, Penn and UNC Chapel Hill. He co-authored Philosophy, Politics, and Economics (Oxford University Press, 2015), and more recently published Creating Future People: The Science and Ethics of Genetic Enhancement (Routledge, 2024).

​Dr. Andrea Cipriano is an esteemed scientist and educator with a profound dedication to unraveling the complexities of cellular biology and aging. He serves as an Instructor at Stanford University's Stem Cell Institute and the Department of Obstetrics and Gynecology, where his research centers on the roles of long non-coding RNAs in cell differentiation and the impact of chromatin structure on aging and its potential reversal. His Ph.D. work focused on the pivotal role of long non-coding RNAs in cell differentiation, a topic that continues to underpin his current research endeavors. In addition to his research, Dr. Cipriano is deeply committed to education. His passion for teaching stems from a belief in the transformative power of knowledge. Beyond his roles at Stanford, Dr. Cipriano contributes to the broader scientific community as a member of the Executive Committee of the Biomarkers of Aging Consortium, where he collaborates with leading experts to develop and validate biomarkers critical for assessing aging and longevity interventions. Through his multifaceted work, Dr. Cipriano aims to advance our understanding of aging processes and foster the development of interventions that promote healthy longevity

Dr. Drew Taylor is an entrepreneur and regenerative medicine pioneer with a diverse background in molecular biology, biomedical engineering, and professional athletics. He is the co-founder and Chief Executive Officer of Acorn Biolabs, a Toronto-based healthcare technology company specializing in non-invasive, follicle-based live cell collection and preservation for personalized regenerative medicine. Prior to founding Acorn Biolabs in 2017, Dr. Taylor served as Chief Science Officer at Epic Capital Management, where he engaged with the burgeoning biotech startup community. He also contributed to the Bioengineering of Skeletal Tissues Team at Mount Sinai Hospital, focusing on cartilage regeneration research. Through his leadership at Acorn Biolabs, Dr. Taylor is committed to making regenerative medicine accessible and personalized, enabling individuals to preserve their cells for future therapeutic use.

Hannah Janjua is an entrepreneur and biomedical scientist focused on accelerating biotechnology through innovative decentralized platforms. She is the Co-Founder and Head of Ecosystem Development at PeptideDAO, a pioneering venture accelerating peptide research to transform health ecosystems. Hannah's scientific background includes a BSc in Biomedical Sciences from King's College London, where she showcased entrepreneurial leadership by securing a silver medal for an Alzheimer's treatment project at the prestigious iGEM competition. Her expertise bridges biomedicine, strategic partnership development, and practical innovation, aiming to unlock impactful solutions for real-world health applications.

Erika is a former astronomer and current synthetic biologist.  In 2021 she founded The Align Foundation, a nonprofit improving the reproducibility, scalability, and shareability of life science research. Align aims to make it easy to build upon the methods and data of other scientists, allowing scientific fields to accumulate data assets to train AI models.

Tim Maupin is a New York City-based director, visual effects artist, and Emmy Award-winning cinematographer with over a decade of experience in the film industry. Demonstrating a profound interest in the longevity movement, Tim directed "The Last Generation to Die," a short film set in a future where science begins to halt aging, which is currently in development as a full feature film. Furthering his dedication to the field, Tim produced the "Lifespan Docs" series for Lifespan.io, featuring short documentaries that delve into personal stories related to life extension and aging. This series aims to humanize the scientific discourse on longevity by presenting diverse perspectives. Tim is a core member and co-creator of JellyfishDAO, which seeks to fund and promote longevity-focused films, series, and media to reshape public perceptions, inspire audiences, and accelerate societal acceptance of healthy longevity through the power of storytelling. Through his multifaceted projects, Tim Maupin continues to bridge the gap between art and science, utilizing his cinematic expertise to explore and promote the possibilities of human longevity.

​Daniel Sollinger is a veteran filmmaker with a career spanning over four decades, during which he has produced an extensive portfolio of feature films, commercials, and music videos. In recent years, Daniel has channeled his storytelling expertise into the longevity movement. He co-founded JellyfishDAO, a decentralized autonomous organization uniting filmmakers, life extension experts, and blockchain innovators to create media that positively portrays life extension and healthspan technologies. His commitment to the cause is further exemplified by his role in organizing Bloom City, a pop-up village in Los Angeles set for July-August 2025. This initiative brings together longevity thought leaders, innovators, scientists, and entertainment creators to catalyze a cultural revolution prioritizing extended and enhanced human life. Daniel's dedication to merging storytelling with scientific advancement underscores his belief in the power of media to evoke emotions and inspire change within the longevity movement.

‍

Léo Pio-Lopez is a scientist specializing in artificial intelligence, computational biology, and regenerative medicine. He currently serves as an Affiliate Senior Scientist at the Allen Discovery Center at Tufts University, working within Michael Levin's laboratory. His interdisciplinary research integrates AI, cognitive science, and developmental biology to uncover fundamental mechanisms of regeneration, morphogenesis, aging, and cognitive processes across multiple biological scales. With deep expertise in computational biology, deep learning, drug discovery, and bioinformatics, Léo is at the cutting edge of AI-driven approaches to understanding aging and creating targeted therapies. His work aims to harness interdisciplinary strategies to develop innovative solutions for regenerative medicine and promote healthy longevity.

We are the first generation who won’t die.

Michael Andregg builds tech to solve fundamental human challenges and expand life's flourishing across our lightcone. He founded Halcyon, which, developed high-speed, mass-producible electron microscopes and built a "molecular threader" to manipulate single DNA strands aiming at lowering the cost of DNA sequencing. He then founded Fathom, aiming at optical computing and high-bandwidth communication between chips and large memory inference for training AI at scale, now aiming at robotics. Currently, Michael leads Eon, which is developing human emulation technology for scanning people at the cell level to run high-fidelity emulations on cloud GPUs. This tech will help humanity avoid x-risks and gives solid state direct edit access to our own minds and bodies.

‍

Zoltan Istvan is a futurist, entrepreneur, and leading figure in the transhumanist movement, dedicated to exploring the fusion of technology and human biology to overcome natural limitations. He is the founder of the Transhumanist Party and author of "The Transhumanist Wager," a philosophical science fiction novel that has sparked extensive dialogue among futurists. Istvan's diverse career includes experience as a journalist for the National Geographic Channel, where he covered stories worldwide. His work often focuses on futurist and transhumanist themes, aiming to bring attention to the possibilities of enhancing human capabilities through technology.​ In the political arena, Istvan has been an advocate for science and technology's role in society. His diverse background and commitment to exploring the intersection of technology and human potential continue to influence discussions on the future of human enhancement and longevity.

​Sukhjit Takhar is a physician and entrepreneur with over two decades of experience in medical practice and healthcare innovation. He is the Co-Founder and Chief Medical Officer of PrimaryMD, a concierge primary care practice committed to delivering personalized and proactive healthcare services. Dr. Takhar holds board certifications in Internal Medicine, Emergency Medicine, and Infectious Disease, having completed his medical degree in 1999. He pursued residencies in Internal Medicine and Emergency Medicine, followed by a fellowship in Infectious Disease at UCLA David Geffen School of Medicine. His professional journey includes serving as an Associate Clinical Professor of Emergency Medicine at UCSF Fresno. Dr. Takhar's work focuses on integrating advanced diagnostics, preventive strategies, and lifestyle interventions to enhance patient health outcomes and longevity.

Mikhail Batin is a Russian entrepreneur and activist dedicated to combating aging and extending human lifespan. He is the co-founder and CEO of Open Longevity, a nonprofit organization that promotes open research and grassroots activism in the field of longevity science. Through initiatives like Open Genes—a database of longevity-related genes—and Aging Nets, which applies network science to aging, Batin aims to democratize aging research and involve the public in scientific endeavors. In 2008, Batin founded the Science for Life Extension Foundation, further demonstrating his commitment to advancing longevity research. His advocacy extends to organizing events such as the "Say Forever Day," a monthly campaign where volunteers engage the public in conversations about life extension, raising awareness and fostering community involvement. Batin's career also includes political engagement; he served as a deputy in the Kostroma Oblast Duma and chaired the Federation of Trade Unions of the Kostroma region. His multifaceted approach combines scientific initiatives, public activism, and policy involvement to address the challenges of aging and promote the development of life-extension technologies.

​Joshua Johnson is an Associate Professor at the University of Colorado Anschutz Medical Campus, specializing in reproductive biology and ovarian physiology. He leads a research laboratory within the Divisions of Reproductive Sciences and Reproductive Endocrinology and Infertility, focusing on mechanisms that drive ovarian aging and dysfunction. His research is dedicated to understanding the control of oocyte number within the ovary, particularly mechanisms that support oocyte quality and those leading to oocyte loss due to aging or premature ovarian failure. Dr. Johnson's work aims to identify women at risk of ovarian dysfunction and develop interventions to protect fertility and ovarian function. In addition to his research, Dr. Johnson contributes to medical education, directing reproductive sciences teaching for early-year medical students. He has received recognition for his work, including the Rogerio Lobo Award from the Society for Reproductive Investigation in 2021. Through his work, Dr. Johnson strives to advance our understanding of ovarian biology to improve women's reproductive health.

Dr. Amy B. Killen is a physician, entrepreneur, and regenerative medicine expert with over a decade of experience at the forefront of anti-aging and preventative health. She is the Co-Founder and Chief Medical Officer at Humanaut Health, a tech-enabled longevity clinic franchise launching in 2024, where she integrates cutting-edge therapies to optimize healthspan and human performance. Originally trained and board-certified in emergency medicine, Dr. Killen transitioned into longevity medicine after witnessing firsthand the toll of chronic disease in traditional healthcare settings. In her clinical practice, Dr Killen and her colleague, Dr Harry Adelson, pioneered the Full Body Stem Cell Makeover, one of the most innovative regenerative procedures currently available. Dr. Killen is also the founder of the Human Optimization Project (HOP), a dynamic longevity supplement system and educational platform, and a co-founder of Reputable Health, a Web3 platform for incentivized, AI-guided self-experimentation.

Dr. Bonnie EJ Maven is the founder and CEO of Vertility Health, an early-stage biotech committed to making genetic disease prevention accessible to all parents. Growing up on a small farm in Texas, Bonnie first discovered her passion for biology. She later moved to California to earn her PhD in Developmental Biology from UCSF and Gladstone Institutes. Today, she leads a dedicated team developing cutting-edge sperm-based technologies to empower families with more reproductive options.

Meliza Mokrani is a wellness entrepreneur and certified health coach with over a decade of experience helping individuals cultivate stress resilience and long-term well-being. Her work focuses on nervous system regulation through a blend of science-backed, somatic practices designed to down-regulate stress and support mind-body healing. She is the founder of WORTHY Self-Care Studio, a transformative wellness space in Berkeley, California, and WORTHY Breath & Body, a nervous system-friendly movement and breathwork studio offering trauma-informed workouts for recovery and regulation. Meliza draws on her expertise as a master breathwork facilitator, health coach, and Trauma Specialist—as well as her lived experience as a trauma survivor—to guide people toward real, lasting change. She is also the creator of Regulate & Rise, an eight-week neuroscience-based coaching program that helps participants rewire stress patterns and build emotional resilience. Her work is rooted in a heart-led, human-first approach that makes healing accessible through her studios and the nonprofit WORTHY Wellness Initiative.

‍

Patrick House is a neuroscientist and author with a Ph.D. from Stanford University, where he studied under Dr. Robert Sapolsky. His doctoral research focused on Toxoplasma gondii, a protozoan parasite known for altering the behavior of its hosts. Transitioning from laboratory research to writing, House authored Nineteen Ways of Looking at Consciousness (St. Martin’s Press, 2022) and writes on AI, science, and culture for The New Yorker. He also spent three years at the neurotechnology startup Kernel, which develops non-invasive fNIRS technology. Through his work, House seeks to deepen our understanding of the mind and the narratives that shape human experience.

​Fabio Boniolo is a computational scientist specializing in the application of statistical and machine learning techniques to understand complex diseases such as cancer. He is a Postdoctoral Research Fellow at the Dana-Farber Cancer Institute, Harvard Medical School, and the Broad Institute of MIT and Harvard, where he focuses on pediatric brain tumors and epigenetics. Fabio earned both his B.Sc. and M.Sc. in biomedical engineering from Politecnico di Milano. He completed his Ph.D. at the Technical University of Munich, developing new methods for patient stratification in precision oncology. Actively involved in the biotech startup scene, he collaborates with various venture funds and entrepreneurial associations. In 2021, Fabio served as an Italian delegate to the G7 Youth Summit.

John Hallman is a machine learning engineer with a robust background in artificial intelligence research and applications. Currently, he serves as a Member of the Technical Staff at OpenAI, contributing to the development of advanced AI models. Prior to this role, John was a Machine Learning Engineer at AKASA, focusing on automating administrative tasks in healthcare to enhance efficiency and reduce costs. John's research experience includes an internship at Google Brain, where he concentrated on reinforcement learning projects. He holds a degree in mathematics from Princeton University and was awarded a silver medal in the International Mathematical Olympiad (IMO). His diverse expertise encompasses machine learning, artificial intelligence, and their practical applications across various industries.

Andrew White is a researcher with over 50 peer-reviewed publications and books across the domains of large language models in chemistry, explainable artificial intelligence, statistical mechanics, and chemical engineering. He has won junior investigator awards from the National Science Foundation and National Institutes of Health along with professional and teaching awards for excellence as a chemical engineer. Andrew is an active member of the scientific community as a peer reviewer for over 30 journals, multiple national and private grant awarding institutions, and serves on the Chemical Sciences Roundtable at the National Academy of Science. Andrew is also a science communicator with large followings on X and LinkedIn and has been interviewed in multiple publications such as the New York Times, Bloomberg, Nature, Financial Times, and Science. Andrew serves on multiple scientific advisory boards across biotech. He has contributed to the ongoing debate around safety of artificial intelligence as a GPT-4 red teamer, speaking at multiple policy summits, and visiting the White House to advise multiple agencies.

Stephen Malina is a machine learning engineer and scientist working at the intersection of AI and gene therapy. He is the ML Engineering Lead at Dyno Therapeutics, where he develops and scales machine learning systems that accelerate the design of next-generation AAV gene therapy vectors. His work supports Dyno’s mission to reshape the gene therapy landscape through AI-powered precision. Stephen’s background spans both industry and academic research. He previously served as Dyno’s Head of Engineering and was the Principal Scientist leading the Machine-Guided Design Team. He also conducted research as a Graduate Research Assistant in the Knowles Lab, focusing on applying ML to molecular discovery. Before joining Dyno, Stephen built scalable backend infrastructure as a Senior Software Engineer at Uber and Compass, where he developed high-performance systems for real-time data pipelines and asynchronous image processing. His unique blend of engineering expertise and scientific curiosity now drives innovation in biotech, where he aims to make gene therapies safer, more efficient, and broadly accessible.

Yisong Yue is a professor of Computing and Mathematical Sciences at the California Institute of Technology (Caltech), specializing in the theory and application of statistical machine learning. His research focuses on developing novel methods for interactive and structured machine learning, with applications spanning information retrieval, robotics, and experiment design. In addition to his academic role, Yisong serves as an advisor at Asari AI, where he contributes to designing AI agents capable of complex planning, abstraction, and verification tasks, facilitating collaboration between humans and AI systems.

​Seth Paulson is a seasoned software developer with extensive experience in bioinformatics and computational biology. At the Methuselah Foundation, he contributes to advancing regenerative medicine and extending healthy human lifespan. Seth leads the development of the Biolearn program for the Biomarkers of Aging Consortium, an open-source library dedicated to the implementation and application of aging biomarkers. His expertise in software development and bioinformatics plays a pivotal role in harmonizing existing biomarkers and unifying public datasets to facilitate cross-population validation studies.

​Nathan Cheng is an entrepreneur and investor dedicated to advancing longevity biotechnology. As Co-Founder and General Partner at Healthspan Capital, he focuses on supporting early-stage companies developing therapeutics to extend healthy human lifespan. Nathan also co-founded the Longevity Biotech Fellowship, a nonprofit organization aimed at increasing the number of professionals working in longevity and maximizing their impact. Additionally, he co-founded Vitalism, a movement advocating for prioritizing the fight against aging and death. Beyond his entrepreneurial ventures, Nathan has been instrumental in community building and education within the longevity sector. He served as Program Director for On Deck Longevity Biotech, facilitating connections among individuals aiming to build, join, or invest in revolutionary longevity biotechnology startups. Nathan also founded Longevity Marketcap, a widely read newsletter covering developments in the longevity biotech industry, and Longevity List, a platform featuring jobs, companies, and investors in the field. His multifaceted efforts continue to contribute significantly to the growth and development of the longevity biotechnology community.

‍

​Michael Florea is a genetic engineer and entrepreneur with extensive experience in developing gene therapies and automation technologies. As Co-founder and CEO of Olden Labs, he leads efforts to revolutionize animal research through the integration of artificial intelligence, robotics, and genetic engineering, aiming to enhance the efficiency and reproducibility of preclinical studies. Michael's academic journey includes a Ph.D. from Harvard University, where he focused on gene therapies for longevity, conducting multiple animal studies. Michael's expertise continues to drive innovations at the intersection of technology and biology, particularly in enhancing the scalability and effectiveness of longevity research.

Aubrey de Grey is a biomedical gerontologist and pioneering advocate for the science of aging. He is the President and Chief Science Officer of the Longevity Escape Velocity (LEV) Foundation, an organization dedicated to accelerating the development of rejuvenation biotechnologies. Aubrey is internationally recognized for formulating the SENS (Strategies for Engineered Negligible Senescence) framework—a comprehensive roadmap for repairing the cellular and molecular damage that drives aging. Trained in computer science and later earning a Ph.D. in biology from the University of Cambridge, Aubrey has spent over two decades promoting the idea that aging is a medical condition that can be treated. His scientific and advocacy work has reshaped public and academic discourse around longevity, inspiring a global movement of researchers, investors, and biohackers. Through the LEV Foundation and other initiatives, Aubrey continues to push forward research that aims not merely to slow aging but to reverse its effects—bringing the dream of radically extended healthy lifespan closer to reality.

Tom Roseberry spent many years as an engineer in aerospace manufacturing before developing a strong interest in neuroscience through racing endurance sports. While working as a triathlon coach he retrained as a biologist followed by a PhD in neuro at UCSF. After a brief postdoc, he left academia to work at Neuralink on next-generation brain-machine interfaces. Through a series of startups he gravitated towards drug development, recently as the VP of Engineering, Comp Bio and Drug Development at Loyal. He recently co-founded Olio Labs, which leverages AI to design combination therapeutics with improved efficacy and fewer side effects.

Masataka Watanabe is an associate professor in the Department of Systems Innovation at the University of Tokyo's Graduate School of Engineering. He specializes in theoretical and experimental neuroscience with a focus on consciousness. His research focuses on unraveling the neural mechanisms of consciousness, with particular emphasis on machine consciousness, spiking neural networks, brain-machine interfaces, and mind-uploading. In 2022, Watanabe authored "From Biological to Artificial Consciousness: Neuroscientific Insights and Progress,". This book approaches the problem of emergent consciousness through scientific studies that shed light on the neural mechanism of consciousness, and furthermore, delves into the possibility of artificial consciousness, a phenomenon that may ultimately solve the mystery. The novel lays out a new and credible pathway to mind-uploading through a method to test machine consciousness and a theory hypothesizing that consciousness emerges from a neural algorithm.

Sunjya Schweig is a physician and entrepreneur with over 25 years of experience in integrative and functional medicine. He is the Founder and President of the California Center for Functional Medicine (CCFM), where he emphasizes an individualized, precision medicine approach to managing complex chronic illnesses. In addition to his clinical practice, Sunjya holds an adjunct faculty position at Touro University College of Osteopathic Medicine and has served as volunteer clinical faculty at the UCSF Santa Rosa Residency. He is also a member of the Scientific Advisory Board for the Bay Area Lyme Foundation, contributing to research and education on Lyme disease. Through his work at CCFM and various educational roles, Sunjya is dedicated to advancing personalized, data-driven healthcare solutions that address the root causes of chronic illnesses, aiming to improve patient outcomes and overall well-being.

Freya Chen is the Managing Partner at BGA (Blockchain for Good Alliance), where she leads core strategy, incubation efforts, and strategic partnerships. Passionate about leveraging blockchain to address real-world challenges, Freya actively identifies and supports high-impact projects by connecting them with the right resources and collaborators. In 2024 alone, Freya engaged with over 300 projects, organized large-scale events, built a strong network of 10+ Advisors, and successfully helped key projects secure $1 million in liquidity funding from Bybit. Her work reflects a deep commitment to empowering builders and advancing blockchain’s role in sustainable development.

​Edward Lando is an entrepreneur and investor with a focus on early-stage startups. He is the founder of Pareto Holdings, a venture studio and investment firm that has incubated over 10 companies and invested in more than 25 unicorns. In addition to his work at Pareto Holdings, Edward has co-founded several companies across various industries. He is also an active angel investor, with a portfolio that includes over 100 investments and 21 exits. ​Through his ventures and investments, Edward aims to empower innovative founders and contribute to the growth of transformative companies.​​

​Noor Siddiqui is a computer scientist and entrepreneur pioneering the intersection of genomics and reproductive health. She is the founder and CEO of Orchid, a reproductive technology company that offers whole-genome embryo screening to help prospective parents assess and mitigate genetic risks for their future children. Orchid's platform sequences over 99% of an embryo's genome, providing insights into more than 1,200 conditions, including heart disease, cancer, and neurodevelopmental disorders. Noor's inspiration for Orchid stems from her personal experience; her mother has retinitis pigmentosa, a genetic condition leading to vision loss. This motivated her to develop tools that empower parents with information to make informed reproductive choices. Through Orchid, Noor aims to shift reproductive healthcare from reactive to proactive, offering parents the tools to reduce genetic risks and promote healthier outcomes for future generations.​

Carolina Reis Oliveira is a biotechnology entrepreneur and scientist with a background in stem cell biology, tissue engineering, and immunology. She is the Co-founder and CEO of OneSkin, a Silicon Valley-based company developing topical products aimed at promoting skin health and longevity. Under her leadership, OneSkin has developed OS-01, a proprietary peptide designed to target cellular senescence, a key factor in skin aging. Through OneSkin, Carolina aims to develop interventions that address the root causes of aging, with a focus on maintaining skin health as a component of overall longevity.

Ethan Berg is an entrepreneur and investor with a background in management consulting and private equity. He is the founder of the Winthrop Estate in Lenox, Massachusetts, a meticulously restored Gilded Age mansion that serves as both a private residence and a cultural venue. Under his stewardship, the estate has hosted events such as TEDx Berkshires, chamber music concerts, and literary readings, fostering a space for intellectual and artistic engagement. Prior to acquiring the Winthrop Estate in 2003, Ethan held a position at the Monitor Group, a management consulting firm, and managed a private investment partnership.

Chris Bradley is a serial entrepreneur and technologist with over 15 years of experience in biotech, health IT, and artificial intelligence. He is the founder and CEO of Matter Bio, a longevity-focused company dedicated to preserving genome integrity to combat aging and age-related diseases. Matter Bio employs a hub-and-spoke model to advance multiple scientific breakthroughs, including accurate mutation sequencing, reversal of somatic mutations, and clearance of pathological cells. Under his leadership, the company had a successful closing of seed round funding for the start of a clinical trial in solid state cancer.

‍

​William Matthews is an entrepreneur and technologist with over a decade of experience in business development, operations, and compliance. He is the founder and CEO of Fellow, a men's health startup offering at-home semen analysis, vasectomy testing, and cryopreservation services. Under his leadership, Fellow developed the first FDA-validated, mail-in semen analysis kit, enabling men to assess their fertility conveniently and privately. The company operates the largest semen analysis lab in the U.S., serving both consumers and healthcare providers nationwide.

Steve Bacich is a veteran innovator and executive in the medical device industry with over two decades of experience leading advancements in reproductive and women’s health technologies. He currently serves as President and Chief Operating Officer of NEXT Life Sciences, a pioneering company developing Plan A™, a long-acting, reversible, non-hormonal male contraceptive aimed at transforming global reproductive options. He holds leadership roles across multiple ventures, including Chief Innovation Officer and Board Member at CrossBay Medical. Steve is also the CTO and Founding Partner of MED1 Ventures, a product development fund focused on high-impact ophthalmology and women’s health devices. MED1’s unique approach develops products—not companies—accelerating exits while minimizing investment risk.

Mark Woodward is a machine learning scientist and entrepreneur with expertise in computational biology and digital health. He is the Founder and CEO of Wake Bio, a company focused on accelerating biotech innovation through advanced AI technologies. Mark also serves as the Chief Science Officer at January AI, where he leads the development of predictive models that integrate wearable data and behavioral patterns to improve metabolic health. Mark holds a Ph.D. in Computer Science from Harvard University and both a Master's and Bachelor's degree in Computer Science from Stanford University. He has previously worked as a research resident at Google Brain and has contributed to publications in top machine learning conferences.

​Jarod Rutledge is a scientist and investor with expertise in biotechnology, aging research, and neurodegenerative disease. He serves as Director of Biotechnology and Life Sciences at Starbloom Capital, where he leads investments in over twenty five companies advancing healthspan and longevity with a hundred million capital deployed. Jarod also holds the position of Biomarkers Lead at the Amaranth Foundation, which has funded dozens of high impact research projects and FROs with over fifty million in capital. Jarod earned his Ph.D. in neuroscience and systems biology from Stanford University and conducted postdoctoral research at the European Molecular Biology Laboratory (EMBL). His academic work includes being the first author on a paper in Nature developing the first truly organ-specific aging clocks with plasma proteomics.

Kenneth Lou is a serial entrepreneur with a background in business administration. He is the co-founder and CEO of Mito Health, a health-tech startup that offers AI-powered personalized health plans based on comprehensive bloodwork analysis. Mito Health aims to provide accessible, preventative healthcare solutions to help individuals live healthier, longer lives. Kenneth holds a Bachelor of Business Administration with a minor in Technopreneurship from the National University of Singapore. He participated in the NUS Overseas Colleges program, studying Information Technology. Through his ventures, Kenneth aims to leverage technology to address significant challenges in health and finance, striving to make impactful contributions to society.